Protagonist Therapeutics, Inc Increase (Decrease) in Income Taxes Receivable
Protagonist Therapeutics, Inc (PTGX) reported Increase (Decrease) in Income Taxes Receivable of -$2.69 million for the 12-month period ending 2022-12-31, per its 10-K filed 2025-02-21.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInIncomeTaxesReceivable · last filed 2025-02-21
- Protagonist Therapeutics, Inc increase (decrease) in income taxes receivable for the quarter ending 2022-12-31 was $33.00K, a 96.42% decline year-over-year.
- Protagonist Therapeutics, Inc increase (decrease) in income taxes receivable for the quarter ending 2021-12-31 was $921.00K, a 94.71% increase year-over-year.
- Protagonist Therapeutics, Inc increase (decrease) in income taxes receivable for the quarter ending 2021-09-30 was -$828.00K, a 446.44% decline year-over-year.
- Protagonist Therapeutics, Inc increase (decrease) in income taxes receivable for the quarter ending 2021-06-30 was $931.00K, a 702.59% increase year-over-year.
- Protagonist Therapeutics, Inc increase (decrease) in income taxes receivable for fiscal 2022 was -$2.69M, a 251.32% decline from fiscal 2021.
- Protagonist Therapeutics, Inc increase (decrease) in income taxes receivable for fiscal 2021 was $1.77M, a 79.29% increase from fiscal 2020.
- Protagonist Therapeutics, Inc increase (decrease) in income taxes receivable for fiscal 2020 was $990.00K.
- Protagonist Therapeutics, Inc increase (decrease) in income taxes receivable for fiscal 2019 was -$1.41M, a 697.88% decline from fiscal 2018.
| Period end | Increase (Decrease) in Income Taxes Receivable 3 month | Increase (Decrease) in Income Taxes Receivable 6 month | Increase (Decrease) in Income Taxes Receivable 9 month | Increase (Decrease) in Income Taxes Receivable 12 month |
|---|---|---|---|---|
| 2022-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$2.69M 10-K · filed 2025-02-21 | ||
| 2022-09-30 | -$2.72M 10-Q · filed 2023-11-02 | |||
| 2021-12-31 | $921.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $93.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.02M derived: sum of 3 quarters · filed 2024-02-27 | $1.77M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$828.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $103.00K derived: sum of 2 quarters · filed 2022-11-08 | $854.00K 10-Q · filed 2022-11-08 | $1.33M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $931.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.68M 10-Q · filed 2022-08-04 | $2.15M derived: sum of 3 quarters · filed 2023-03-15 | $2.39M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $751.00K 10-Q · filed 2022-05-05 | $1.22M derived: sum of 2 quarters · filed 2023-03-15 | $1.46M derived: sum of 3 quarters · filed 2023-03-15 | $1.58M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $473.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $712.00K derived: sum of 2 quarters · filed 2023-03-15 | $828.00K derived: sum of 3 quarters · filed 2023-03-15 | $990.00K 10-K · filed 2023-03-15 |
| 2020-09-30 | $239.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $355.00K derived: sum of 2 quarters · filed 2021-11-03 | $517.00K 10-Q · filed 2021-11-03 | $343.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $116.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $278.00K 10-Q · filed 2021-08-04 | $104.00K derived: sum of 3 quarters · filed 2022-02-28 | |
| 2020-03-31 | $162.00K 10-Q · filed 2021-05-04 | -$12.00K derived: sum of 2 quarters · filed 2022-02-28 | ||
| 2019-12-31 | -$174.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$1.41M 10-K · filed 2022-02-28 | ||
| 2019-09-30 | -$1.24M 10-Q · filed 2020-11-04 | |||
| 2019-03-31 | $441.00K 10-Q · filed 2020-05-07 | $773.00K derived: sum of 2 quarters · filed 2021-03-10 | -$286.00K derived: sum of 3 quarters · filed 2021-03-10 | $71.00K derived: sum of 4 quarters · filed 2021-03-10 |
| 2018-12-31 | $332.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | -$727.00K derived: sum of 2 quarters · filed 2021-03-10 | -$370.00K derived: sum of 3 quarters · filed 2021-03-10 | $236.00K 10-K · filed 2021-03-10 |
| 2018-09-30 | -$1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$702.00K derived: sum of 2 quarters · filed 2019-11-06 | -$96.00K 10-Q · filed 2019-11-06 | $364.00K derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-06-30 | $357.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $963.00K 10-Q · filed 2019-08-07 | $1.42M derived: sum of 3 quarters · filed 2020-03-10 | -$586.00K derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-03-31 | $606.00K 10-Q · filed 2019-05-08 | $1.07M derived: sum of 2 quarters · filed 2020-03-10 | -$943.00K derived: sum of 3 quarters · filed 2020-03-10 | -$566.00K derived: sum of 4 quarters · filed 2020-03-10 |
| 2017-12-31 | $460.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | -$1.55M derived: sum of 2 quarters · filed 2020-03-10 | -$1.17M derived: sum of 3 quarters · filed 2020-03-10 | -$1.07M 10-K · filed 2020-03-10 |
| 2017-09-30 | -$2.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$1.63M derived: sum of 2 quarters · filed 2018-11-06 | -$1.53M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $377.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $479.00K 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | $102.00K 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | $1.59M 10-K · filed 2019-03-12 | |||
| 2015-12-31 | $192.00K 10-K · filed 2018-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |